Preference, Persistency and Positioning for Lilly’s Taltz in Psoriasis Highlight a Potential Challenge Ahead for Novartis’ Cosentyx in PsO and Psoriatic Arthritis

Spherix Global Insights has released the results of two independent surveys of dermatologists (n=100) and rheumatologists (n=100) about the evolving practice patterns in the management of psoriasis (PsO) and psoriatic arthritis (PsA). Download Report Overview: Psoriasis Download Report Overview: Psoriatic Arthritis CAMBRIDGE, MASSACHUSETTS (PRWEB) APRIL 17, 2017 Despite positive perceptions, and brand expansion from the

Psoriasis and Psoriatic Arthritis Markets Undergo Big Changes as IL-17s, such as Novartis’ Cosentyx and Lilly’s Taltz, Increase Penetration

IL-17s stop Janssen's Stelara in its tracks and while Cosentyx holds out as the only approved IL-17 in PsA, competition is looming - according to a recent study by Spherix Global Insights CAMBRIDGE, Mass., April 4, 2017 /PRNewswire/ -- Spherix Global Insights has just released the results of two independent surveys of 200 rheumatologists and

Roche Nabs FDA Approval for “Game-changing” Therapy for the Treatment of Multiple Sclerosis

The Q1 edition of RealTime Dynamix™: Multiple Sclerosis published by Spherix Global Insights finds that adoption of Ocrevus will be quick for patients with primary progressive multiple sclerosis, but uptake will be more muted in patients with relapsing forms of the disease Download Report Overview: RealTime Dynamix Q1 Download Report Overview: RealWorld Dynamix - DMT

Pre-launch Intentions for Sanofi-Regeneron’s Dupixent (dupilumab) Suggest Rapid Uptake in an Area of High Unmet Need

100% of surveyed dermatologists see a role for Dupixent in their practices with most anticipating quick adoption according to a recent independent study by Spherix Global Insight Download Report Overview March 20, 2017 – Cambridge, Massachusetts. The future treatment of atopic dermatitis got a whole lot brighter yesterday with the approval of Sanofi-Regeneron's Dupixent, the

Relypsa’s Veltassa Dodges the Competition Bullet as FDA Hands AstraZeneca a Second Complete Response Letter for Hyperkalemia Agent, ZS-9

Delay gives Relypsa time to close the nephrology-to-cardiology gap for Veltassa Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Sixteen months and $2.7 billion ago, ZS Pharma’s hyperkalemia candidate (ZS-9, sodium zirconium cyclosilicate) was one of the most highly anticipated drugs in the renal market.  Since being acquired by AstraZeneca, the company last week